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In this article, we identify and discuss a timeline of historical events and scientific breakthroughs that shaped the
principles of tissue engineering and regenerative medicine (TERM). We explore the origins of TERM concepts
in myths, their application in the ancient era, their resurgence during Enlightenment, and, finally, their sys-
tematic codification into an emerging scientific and technological framework in recent past. The development of
computational/mathematical approaches in TERM is also briefly discussed.
Introduction
It is in the timbres of past that the future is echoed. Thisis particularly applicable to the realm of technology, which
clearly has a cumulative character. The fact that a lot of
technologies find their precedent in myths should therefore
come as little surprise, for myths shape ideas, and ideas
technologies. Tissue engineering and regenerative medicine
(collectively TERM, henceforth), therapeutic techniques that
rely on, both in vivo and ex vivo, reactivation of develop-
mental processes to form products that can help alleviate
healthcare problems related to the diseases of cellular defi-
ciency,1 including loss of tissue/organ functionality due to
trauma, share this template too. Where the objective of tissue
engineering is to produce functional, preferably autologous,
substitutes that can improve or replace a failing tissue2–5;
regenerative medicine, as per Daar and Greenwood6 and
Mason and Dunnill,7 aims to ‘‘repair, replace or regenerate
cells, tissues, or organs to restore impaired function.’’6–8
Already, despite the fields being in their nascence, examples
abound of successful clinical implementation9: corneal sur-
faces,10 replacement of bronchial segment,11 reconstitution of
bone,12 as well as cartilage13 defects and diseased bladder.14
On the same note, external support devices such as extra-
corporeal liver15 or engineered tissues that can serve as
in vitro models to investigate pathogenesis, stem cell be-
havior, and developmental processes, in addition to devel-
oping new molecular therapeutics,16–18 further underpin the
capacity for therapy and knowledge on offer.
The toolkit employed to achieve this includes, but is not
limited to: (stem) cells, controlled release matrices (syn-
thetic and natural), scaffolds, soluble molecules (nucleic
acids, proteins, hormones, even viruses) directing cell
function, and bioreactors. The applicability of each of these
components is discussed in detail in The Principles of Tissue
Engineering.19 There are of course slight differences dis-
tinguishing the two fields, which, according to Daar and
Greenwood,6 include a broader range of methodological
alternatives available to regenerative medicine, such as ge-
netic engineering of cells followed by their transplantation
and pharmaceutical targeting of developmental pathways.
Nevertheless, they are treated collectively in this article
since the underlying goals (repair, regeneration, replace-
ment, and restoration of impaired function),6 tools (involv-
ing either isolated cells or substances that induce tissue
growth, or cells placed on/encapsulated within a biocom-
patible scaffold),3 and, more importantly, principles (as we
discuss in this article) are almost identical in both cases.
In this article, we explore the origins and historical de-
velopment of the principles that are responsible for the
availability of, possibly, the most promising healthcare
technology ever put forward. Given space constraints, the
events catalogued herein were chosen based on their rele-
vance to the aforementioned toolkit. Additionally, the de-
velopment of theoretical and computational concepts is
discussed, albeit very briefly. We conclude with a concise
review of the current status of TERM followed by a glance
at some immediate and long-term frontiers of the future.
A Timeline of the Development of TERM
TERM in myth and art
While the principles of TERM acquired their current
form in the late 20th century, conceptually—and even
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practically—these principles are as old as humanity. The
concept of totipotencya first finds expression in the Hindu
myth of Raktabeej (Rakta = blood; beej = seed); an Asurab
whose blood drops could form his clones ex vivo.c Quite apt
then that stem cells, some of which possess a totipotent
character, were first reported in 1963 by the hematopoietic
community.20 We first encounter, in Hesiod’s Theogony
(lines 507–616) circa 700BC, in vivo regeneration in the
Greek myth of Prometheus; a Titan who stole fire from Zeus
to offer it to humanity and was sentenced to a lifelong cycle
of misery where his liver, pecked out by an eagle, would
regenerate each day to prolong his suffering. The applica-
tion of a bioreactor to support and stimulate development ex
vivo is first documented in the great Indian epic, Ma-
habharata, which tells the story of the birth of the Kaurava
brothers. After 2 years of pregnancy, their mother produced
a mass of flesh, which a sage divided into a hundred parts
that were kept in pots treated with herbs and ghee (a form of
butter)—the combination of both, presumably, serving as
culture media—for 2 additional years.21 At the end of the
second year, each pot produced a viable human, and thus, a
hundred Kaurava brothers were born. The oldest preserved
parts of the text are considered to be written circa 400BC.
This, quite possibly, also constitutes the first reference in
human history to perfusion culture. In modern fiction, a
bioreactor appeared in the laboratory scene of Faust Part II,
published in 1832, as the phial employed to create the ho-
munculus.22 Both the pots in Mahabharata and the phial in
Faust were clearly meant to be used as devices that could
provide controlled environments to support (ex vivo) de-
velopment, much like a uterus would in vivo.
Rig Veda, considered to be compiled between 3500 and
1800BC, contains the first mention of a biomaterial. Queen
Vishpala, who was amputated in a battle, was fitted with an
iron leg once her wound healed enabling her to return to the
battlefield.d Another example of the use of a prosthesis
occurs in the Greek story of Hegesistratus, who in order to
escape his Spartan captors cuts off his own foot and later
replaces it with a wooden one, as narrated in the ninth Book,
Chapter 37, of the Histories by Herodotus. The article was
published circa 400BC.
Ancient applications of TERM principles
From the practical perspective, wound closure through
the application of sutures has been known to exist since the
Neolithic period (10,000BC).23 The range of materials
varied from synthetic (linen by Egyptians), to natural (catgut
by Europeans), and biological (heads of large biting ants in
the Indian subcontinent and South Africa).23 Skin grafts
were first employed in the Indian subcontinent as early as
2500BC,24 with Susruta, the father of Surgery, at the
forefront of this technology. Susruta employed free gluteal
fat and skin grafts to treat the mutilations of the ear, nose,
and lip.24 Variations of the procedure, among others, in-
cluded ‘‘slapping the skin of the buttock with a wooden
paddle until it was quite congested and then, with a leaf cut
to proper shape as a pattern, cutting out a piece of skin with
its subcutaneous fat, transplanting it and sewing it into
place, uniting it to the freshened edges of the defect.’’25 The
Papyrus of Ebers presented us with the most classical ex-
ample of TERM; cell-supportive scaffold guiding regener-
ation: Egyptians, around 1500BC, treated skin wounds
using lint, grease, and honey,26 where honey served as the
antibiotic—presumably due to its hypertonicity—and grease
provided a barrier to the entry of pathogens26; lint acted as
the fibrous scaffold that would promote wound regenera-
tion.26 Metallic sutures have been documented to be in ap-
plication since the second century AD in Greece and were
described by the physician, surgeon, philosopher Galen of
Pergamon (129–216).23
One of the earliest evidence of the use of biomaterials
comes from a mummified body discovered in Egypt. Pa-
leopathological examination of this mummified woman
showed that the big toe of her right foot was amputated. The
missing toe, however, was replaced by a ‘‘delicately man-
ufactured’’ wooden one.27 Additional evidence of Iron being
used as a biomaterial stretches as far back as the Gallo-
Roman period. Crubezy et al.28 reported a skull from that
era containing an osseointegrated dental implant of a right
second upper premolar. Pieces of blue nacre shell, which
achieved successful osseointegration,29 were employed as
dental implants by the Mayans as early as 600AD.23,30
Enlightenment and the growth of TERM principles
While a lot of practical information from the medieval era
was lost, TERM concepts managed to survive as art forms
and myths, refer to Figure 1, and with the advent of the age
of Enlightenment started to regain lost momentum. The
Enlightenment period (late 17th century to the end of 18th
century) was the first significant milestone in the history
of TERM; in many ways, it sparked the revolution that
provided impetus for the birth of this technology. The En-
lightenment era brought with it an emphasis on the empir-
ical sciences, as well as a push toward objectivity and a
reasoned approach to study nature.31 Experiments became
an integral part of this reasoned approach.31 It was during
this era that philosophers started investigating the phe-
nomena of reproduction and regeneration to understand the
origins and governing dynamics of life.
The mechanistic thought gained prominence with Rene
Descartes, who concluded that ‘‘all natural objects were
caused by inert particles of matter in motion,’’31 followed by
Sir Isaac Newton’s understanding of man as a complex
physicochemical machine and disease as a fault in that ma-
chine.32 The mechanical philosophy, thus, emerged as the
medium to explore physiological phenomena. Giovanni Al-
fonso Borelli (1608–1678), for example (Fig. 2), explained
muscular contraction as a hydraulic inflation.31 The me-
chanical philosophy was, however, unable to account for truly
complex phenomena, such as regeneration, reproduction, or
aThe ability of a cell to divide and produce all the differentiated
cells of an organism.
bAccording to Rig Veda, Asuras are a group of power-seeking
deities that preside over moral and social phenomena.
cThe legend of Raktabeej appears in the eighth chapter of Devi
Mahatmya, which forms a part of Markandeya Purana. The Purana
is supposed to have been composed around 400–500CE, although
establishing the origin is difficult, for a lot of Hindu literature ex-
isted in oral form before it was printed.
dThe authors gratefully acknowledge the translation of the rele-
vant Sanskrit hymns found in the Rig Veda (10th Mandala, 39th
Sukta) into Hindi by Neelam Kaul.
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FIG. 1. Tissue engineering
and regenerative medicine in
literature and art. (Left) The
figure depicts transplantation
of a leg by Saints Cosmas
and Damian. The twin
Christian martyrs were phy-
sicians and lived during the
third century. The painting
shown in the figure was cre-
ated in the late 15th century.
(Right) The figure shows the
use of a phial, representing a
bioreactor, in the engraving
of Homunculus from
Goethe’s Faust, Part II.22 The
play was published in 1832.
Both figures belong to the
public domain.
FIG. 2. Mechanistic physiology. G.A.
Borelli’s De Motu Animalium (on the motion
of animals) (1680) looks at the human body
as a machine functioning as a system of le-
vers and pulleys demonstrated in the figure
along with leg joints and the action of
muscles in balancing the body. The sub-
figures show Borelli’s analysis of various
joints in humans (adapted from Pope153). (1)
Conjunction of two levers (IFS and HDR in
the figure) at pivot point C. (2) Role of
elastic bands (muscles) attached to the levers
(at D and F) and the pivot (B) in bringing the
levers closer together. (3) The role of the
elastic bands in ‘‘expanding’’ the levers. (4)
A system composed of multiple levers of
unequal length. (5, 6) Muscle and bone
configurations in humans carrying different
loads. (7, 8) Investigations in pulley ar-
rangements. (9, 10) Muscular action that
enables a human to hold a weight with an
extended arm. While the mechanistic ap-
proach was able to explain the motions of
bones, muscles, and, even, the heart, it was
not able to capture the vital functions of the
human body. The figure was derived from
the digital copy of Borelli’s De Motu Ani-
malium (1680) and reprinted under the
Creative Commons Attribution License.
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even growth. We need to be reminded though that even to-
day, current computational and theoretical methodologies still
struggle to account properly and capture some of this com-
plexity. As a result, 18th century physiology, influenced by
experimental physics and chemistry, adopted a more phe-
nomenological approach.31
In 1663, 2 years before Robert Hooke discovered the cell
and two centuries before Rudolf Virchow’s (1858) ‘‘omnis
cellula e cellula,’’e Benedict de Spinoza (1632–1677) in a
letterf to Henry Oldenburg, the first secretary of the Royal
Society, opined the existence of homeostasis and dynamic
cross talk between various elements within the body. He
wrote, ‘‘All natural bodies can and ought to be considered in
the same way as we have here considered the blood, for all
bodies are surrounded by others, and are mutually deter-
mined to exist and operate in a fixed and definite propor-
tion, while the relations between motion and rest in the sum
total of them, that is, in the whole universe, remain un-
changed.’’33 Benedict de Spinoza, in his Newtonian articu-
lation, thus laid, what perhaps can be called the foundation
of modern TERM.
One of the most remarkable sets of experiments in this
period was conducted 80 years later by Abraham Trembley
(1710–1784) who was investigating the regenerative capa-
bility of hydra (Fig. 3). Each time he cut a hydra, irre-
spective of the body axes or number of pieces, he observed
regeneration of the entire organism from each piece.31,34
The results, published in 1744, provided the first glimpse
into the regenerative potential of the cell. The conclusions
were revolutionary, for regeneration, until then, as observed
in salamanders and crabs, was considered a property of the
organism,31 and not the cell.
Making the assumption that humans had some apprecia-
tion, however rudimentary, of the concept of bioreactivity
is probably justified, because of, one would presume,
everyday life experience on the ill-effects of using a non-
biocompatible material. However, the first-documented
instance of evaluating in vivo bioreactivity of implant ma-
terials only occurred in the first half of the 19th century.
Henry S. Levert, an American doctor, in 1829, began testing
the efficacy and safety of various metallic sutures on dogs.
Levert reported superior performance of platinum sutures
over those made of gold, silver, and lead.35 The next few
decades witnessed a departure from the use of splints and
braces to fix bones, with application of metal screws and
plates garnering considerable medical interest23 toward
this end. About a century later, in 1924, Arthur Zierold,
building on the investigations conducted by Levert, reported
on the ill-effects of using materials, such as iron and steel
(rapid corrosion); copper, aluminum, and zinc (tissue dis-
coloration); and gold, silver, lead, and aluminum (lack of
mechanical robustness).36 It was not until the discovery of
stainless steel technology, according to Buddy Ratner,23 that
the routine use of metals in the body, at reasonable cost,
became the mainstream.
During the first half of the 19th century, Christian H.
Pander (1817) hypothesized the dependence of tissue de-
velopment on a dynamic interplay between cells and their
FIG. 3. Trembley’s polyps. The ability to regenerate an
entirely new polyp from a severed part made polyps closer to
plants. But their ability to move and hunt to feed themselves,
as shown in this illustration from Trembley’s ‘‘Memoires pour
server a l’histoire d’un genre de polypes d’eau douce, a bras
en forme de cornes’’ (Memoir on the natural history of a
species of fresh water polyps) (1744), suggested they were
animals. Their regeneration, however, contradicted the Pre-
formation theory. (1–9) Planche 3 (top) display two different
styles of locomotion adopted by a polyp. In Planche 13
(bottom), Trembley’s attempts to unite one polyp inside an-
other are displayed. (1) State of two polyps after one had been
passed through another. The external polyp is represented as
‘‘a b’’ and the internal polyp as ‘‘c d.’’ (2) Internal polyp
splitting the lower part of the external polyp at i. (3) State of
the two polyps following a meal ingested by the internal
polyp. They are both dilated, including the foot of the external
polyp, which indicated communication between the two pol-
yps. (4) The internal polyp (c d) splits the upper region of the
external polyp (a b) and emerges at o. The inner polyp is now
represented by c o i d. (5)Dilation is again observed following
a meal ingested by the external polyp, indicating that the two
polyps share the same interior.154 (6) After maintaining that
state for more than a month, and following multiple cycles of
nourishment, the two polyps display growth and division.
Here, the inner polyp is represented by c o i d; the external by
a i b; and the progenies by e. (7)A constriction appears at n on
the neck of the grafted polyp (c d in frame [1]) two months
after transplantation. n acts as the point of separation for the
head of the internal polyp (c d), which detaches itself (not
shown here) a month after the formation of this constriction.
The authors gratefully acknowledge Polly Akhurst (BA Hons,
Oxon) for translation of relevant text from French to English.
Planche 3 (top) was derived from the digital copy of Mem-
oires Pour Server A L’histoire D’un Genre De Polypes D’eau
Douce, A Bras En Forme De Cornes, and reprinted under the
Creative Commons Attribution License. Planche 13 (bottom),
which originally appeared in Trembley’s ‘‘Memoires...,’’ was
reprinted from British Journal of Plastic Surgery, 19, Tom
Gibson, ‘‘The first homografts: Trembley and the polyps,’’
301–307, ª (1966), with permission from Elsevier.
eCells arise from preexisting cells.
fLetter XV. (XXXII.): Spinoza to Oldenburg.
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surrounding microenvironment37,38 (Fig. 4). Forty years later,
in 1858, Rudolf Virchow proposed that tissue regenera-
tion depended on cellular proliferation.39 This resulted in
pioneering efforts to grow cells ex vivo, first suggested by
Leo Loeb in 1897.40 It was also toward the end of the 19th
century that the phrase stem cell,g owing to research on the
development and regeneration of the hematopoietic system,
first made its appearance in the scientific literature.41 It
would take investigators working on the hematopoietic
system another 60 years to actually prove the existence of
these versatile precursor cells.
Ex vivo cell growth was finally achieved42 in 1910 in a
seminal piece of work by Ross G. Harrison (1870–1959)
who was primarily motivated to determine whether nerve
fibers originated from nerve cells of the central nervous
system or were secreted by cells of the tissues through
which the nerve fibers eventually passed. Harrison investi-
gated this by forming a hanging-drop culture.43 He ex-
planted a fragment from the nerve cord of a frog tadpole into
a drop of frog lymph on a coverslip that was inverted and
sealed to a hollow-ground slide and observed the growth of
nerve fibers pushing their way through the lymph.18,40,44
The article42 reporting the findings is considered as probably
‘‘the most important paper ever published in the Journal of
Experimental Zoology.’’45 The discovery of contact inhibi-
tion,46 the observation that cells cease their movement upon
‘‘collision’’ rather than sliding past each other, is attributed
to the hanging-drop culture44 study.
Alexis Carrel (1873–1944), recipient of the 1912 Nobel
Prize in Medicine, extended this work by growing cells of
endothermal animals ex vivo, and, in his efforts toward
developing a methodology to grow cells in large numbers,
invented the technique of cell culture. Carrel’s culture
techniques involved embedding tissue fragments in a thin
layer of clotted plasma (presumably analogous to the modern
scaffold), which was maintained under a fluid phase (usually
of embryo extract) that had to be replaced every few weeks.
Once confluent, several pieces of the clot would be used to
seed new flasks.44 An editorial published in the Journal of the
American Medical Association in 1911 opined that Carrel’s—
along with Montrose T. Burrows’ (Carrel’s colleague at the
Rockefeller Institute)—efforts have laid bare ‘‘practically a
whole new field for experimental attack on many of the most
fundamental problems in biology and the medical sci-
ences.’’47 By 1912, the technique of tissue culture (Fig. 547)
had been firmly established.48
FIG. 4. The development of the embryo as a result of
interactions between primordial tissue. Christian Heinric
Pander (1794–1865)38 is attributed to have played a major
role in our understanding of the development of germ layers
that are responsible for the generation of the organ systems
of organisms. Pander, in collaboration with Do¨llinger and
d’Alton, observed chicken embryos from several thousand
incubated eggs using a methodology155 that enabled them to
describe early development with unprecedented accuracy.
Pander reported, in the surface of the yolk, a developing thin
and delicate membrane, that is, the embryo, which he coined
the ‘‘blastoderm.’’156 The drawing, by d’Alton, demon-
strates the earliest observation of circulation in the chicken
embryo—a later stage in embryonic development.155 His
findings were linked to induction and interactions between
the primordial tissue that help devise the body plan without
intervention from an external principle. Pander’s work,
validating the theory of Epigenesis, was a strong blow to the
now annulled preformation theory, quite popular at the time.
The authors gratefully acknowledge Elisabeth Forster
(DPhil Candidate, Oxon) for translation of relevant text
from German to English. The figure was derived from the
digital copy of Pander’s Beitrage zur Entwickelungs-
Geschichte des Huhnchens im Eye and reprinted under the
Creative Commons Attribution License.
FIG. 5. The beginnings of tissue culture. The figure shows
two technicians working in the Carrel laboratory at the
Rockefeller Institute. They are wearing full-length black,
hooded gowns that were adopted by Carrell.47 The image
first appeared as Figure 23 in R.C. Parker’s ‘‘Methods of
Tissue Culture,’’ New York, Paul B. Hoeber (erstwhile
Medical Book Department of Harper & Brothers), 1938.
Reproduced with kind permission of HarperCollins.
gA precursor cell with limitless proliferative potential capable of
forming more specialized cells.
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Carrel’s observation that fragments of embryonic chick
heart explanted into blood plasma supplemented with saline
extract of embryonic tissues could maintain a state of active
growth for long periods49 was important, for it supported
Pander’s hypothesis of the interdependence of cells and their
environment toward tissue development. But, in terms of the
development of culture media, an essential tissue engi-
neering material, this observation constituted a significant
advance47 and a push to move away from using saline
culture media, which had dominated the scene until then.
While the development of the culture technique and ad-
vances in the composition of culture media solved, to an
extent, the problem of growing cells in vitro, the cultured
cells failed to demonstrate much beyond survival and pro-
liferation.44 This was partly due to the fact that to develop
into tissues, cells require spatial as well as mechanical cues
that primitive culturing scaffolds were unable to provide,
and, second, an increased metabolic demand that static
cultures often failed to meet. The need for a perfusion de-
vice had arisen.
In 1930, Carrel, interested in ex vivo perfusion of organs,
was joined in his investigations by the great American
aviator Charles A. Lindbergh48,50 (1902–1974). Lindbergh
was motivated by the death of his sister-in-law who had
rheumatic valvular disease48 and could not undergo surgery
on her mitral valve due to the absence of any means to
perform temporary heart bypass.50 Lindbergh met Carrel on
the recommendation of one of his sister-in-law’s physi-
cians,48 and the two together created a continuous perfusion
flask that can provide a tightly controlled environment to
sustain organs ex vivo. The perfusion chamber could addi-
tionally provide pulsatile circulation under sterile conditions
and had the means of controlling the composition of the gas
in the circulating ‘‘perfusion fluid’’ as well as the exterior of
the organ.48 While the brewing industry had employed in-
dustrial scale bioreactors aimed at controlled fermentation
for centuries until then, this was the first application of the
bioreactor as it is known in the TERM sector. Carrel was
able to keep a human thyroid ‘‘alive and in good condition’’
in the Lindbergh apparatus, shown in Figure 6, for at least 3
weeks and in a usable condition for 1–2 months.51
The dark and sullen backdrop of the two world wars,
exacerbated and prolonged by the immeasurably superior
(compared with previous years) technological advances
made during the Industrial revolution, which enabled the
mass production of weapons with enhanced accuracy,
power, and range, had profound (social, economic, material,
ethical, and philosophical)52 consequences. However, sci-
entific advancements during the war years, which witnessed
peacetime availability of newly developed high-perfor-
mance materials (metals, ceramics, and polymers) and their
application by surgeons to address a multitude of medical
problems,23 constituted a few instances shining brightly
against that background. The brightest of them being the
serendipitous observations of Sir Harold Ridley (1906–
2001), which even to this day23 form the touchstone for
clinical acceptability and efficacy of implants.
Following the Second World War (1939–1945), Sir Harold
observed53 in aviators who had retained in their eyes
splinters of plastic from shattered canopies in Spitfire and
Hurricane fighter planes stable, noninflammatory, and non-
irritable healing of these unintentionally implanted shards.23
The widely held view23 at the time was that human body
could not tolerate foreign objects. Sir Harold’s observation,
therefore, constituted a paradigmatic advance, for it was
‘‘perhaps the first’’23 observation of biocompatibility in
humans, as per the currently held definition of the concept.
Sir Harold went onto use poly(methyl methacrylate) to
fabricate intraocular lenses, which were employed as sub-
stitutes for natural lenses clouded by cataracts.53 Ignoring
the—extremely important in its own right—matter of rev-
olutionizing the treatment of individuals suffering from
cataract, Sir Harold’s observation that foreign objects can
indeed be compatible with the human body proved catalytic
to the development and availability of other implants.23
The concept of osseointegration shares similar fortuitous
origins as that of biocompatibility. Per Ingvar Bra˚nemark,
an orthopedic surgeon based in Sweden, was involved, since
FIG. 6. The Lindbergh pump. The figure shows the Py-
rex glass-based pulsating perfusion pump developed by
Charles Lindbergh and Alexis Carrel. The perfusion pump,
along with its inventors, appeared on the cover of Time in
1935. The apparatus consisted of two portions: the perfusion
pump containing the organ and perfusion fluid, and the other
for ‘‘creating and transmitting a pulsating gas pressure to the
perfusion fluid contained in the first.’’138 The perfusion
pump involved the use of three chambers, one above an-
other. The lowest chamber served as fluid reservoir, which
was maintained under a pulsating pressure and passed fluid
to the organ chamber (highest). After passing through the
organ, the fluid returned to the reservoir through the (cen-
tral) equalization chamber. The perfusion pump shown in
the figure was photographed by Louis Schmidt and Joseph
B. Haulenbeek, and was reprinted fromª (1935) Lindbergh,
Journal of Experimental Medicine, 62:409–431, with per-
mission from Rockefeller University Press.
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1952, in investigations pertaining to tissue-integrated pros-
theses and healing reactions.54 Following the conclusion of
a study, in early 1960s, in which a titanium cylinder had
been screwed into the bone of a rabbit, Bra˚nemark observed
the integration of the implant into the bone.55 He coined the
phenomenon ‘‘osseointegration.’’54,55 Go¨sta Larsson, who
had a cleft palate defect, was the first human patient to
receive a dental implant, which remained functional until
the subject’s death in 2006.56 To further put the implant’s
functionality and shelf-life into perspective: Bra˚nemark had
conducted the procedure in 1965.
Currently, titanium metal and alloys are the premier
choice of materials for dental and orthopedic implants.23 By
1954, the first prosthetic vascular graft developed from a
silk handkerchief and Vinyon ‘‘Y’’ (the then parachute
fabric) had been implanted in a human patient.57 The in-
novation was inspired by Arthur Voorhees’ observation that
an implanted silk suture traversing the chamber of the right
ventricle of a dog’s heart ‘‘became coated in a few months
throughout its length by a glistening film, free of macro-
scopic thrombi.’’58 For a detailed history of biomechanical
implants and grafts, we recommend perusing the historical
review on Biomaterials by Buddy Ratner.23
With the advent of digital computing machines, the second
quarter of the 20th century also witnessed several efforts to
enhance our quantitative understanding of development and
regeneration. In 1930, Nicolas Rashevsky coupled chemical
reactions with mechanical processes in cells to make sense of
morphogenesis,59 and in doing so attempted to unite the
phenomenological aspect of physiology with the mechanistic
philosophy. Rashevsky assumed cells to be spherical entities
and considered only abstract patterns of chemical reactions
occurring across and within their boundaries.60 It was, how-
ever, an article published in 1952 by the British mathemati-
cian and cryptanalyst, Alan Turing (1912–1954) that marked
a seismic event that contributed, albeit indirectly, to further
advances of TERM. In his seminal article, The Chemical
Basis of Morphogenesis,61 Turing investigated coherent pat-
terns of permanence (in a statistical sense) that would emerge
out of instabilities disturbing the homogeneous equilibrium of
reaction–diffusion systems and presented, arguably, the first
computational model of a biological phenomenon, founded
on first principles.
Turing was particularly interested in the onset of these
instabilities that force a system out of its equilibrium, to-
ward a new stable state. Turing demonstrated that coupling
the chemical reactions occurring within cells with the dif-
fusion of these chemicals could give rise to complex dif-
ferentiation patterns. His findings heralded a new era of
computational models where his reaction–diffusion equa-
tions, complemented with nonlinear coupling between the
chemical reactants and kinetic data, became the ‘‘universal
mathematical language for describing the biochemistry of
spatiotemporal pattern formation in cells and developing
organisms.’’60 His conclusion, ‘‘[.] principles which have
been discussed, should be of some help in interpreting real
biological forms,’’ now forms the basis of the computational
TERM/biology sector.
John von Neumann (1903–1957), Turing’s eminent peer,
was the scientific computing pioneer who recognized the
dependence of an ‘‘automaton’’ on the ‘‘milieu’’ it consti-
tutes a part of as well as responds to. In a series of lectures,
von Neumann stated, ‘‘[.] it’s meaningless to say that an
automaton is good or bad, fast or slow, reliable or unreli-
able, without telling in what milieu it operates,’’62 thus
contextualizing the hypotheses proposed by Spinoza and
Pander as well as the observations of his contemporary
experimentalists using computational parlance. His investi-
gations on self-replication and biological pattern formation
led to the birth of automata theory,60,62 which provides ar-
guably the most suitable ontology to represent biological
systems. Von Neumann, furthermore, viewed organisms as
composed of ‘‘analog’’ (or continuous, in the mathematical
sense) and ‘‘discrete’’ elements.62 The increasingly popular
hybrid models find at their heart Von Neumann’s attempt to
unify63 the two.
The modern history
The discovery of stem cells was beyond doubt a signifi-
cant event in the history of medicine. Along with experi-
mental observations regarding cell growth and histogenesis,
many of which came from investigations conducted by Ju-
dah Folkman (1933–2008), it kick-started the early modern
history of TERM. Coming to the fore in the early 1960s,
stem cell research fueled the remarkable advances in
TERM. While it was not until the 1990s that the use of stem
cell and tissue engineering concepts merged to produce el-
egant solutions to healthcare problems arising due to cellular
deficiency and/or physical trauma, transplantation of stem
cells had started as early as 1968.
Stem cells. Although the concept of stem cells, as the
kind of cells capable of forming cells of a different, more
specialized, phenotype, emerged in the late 19th century, it
was not until 1960s that the existence of these multipotent
cells was first validated. Becker et al.20 reported, in murine
spleen, colonies of dividing hematopoietic cells, some of
which were differentiating ‘‘into cells of erythrocytic, gran-
ulocytic and megakaryocytic series, respectively.’’20 Altman
and Das, in 1965, published evidence of postnatal neurogen-
esis,64 but their report was largely ignored as neurogenesis
was, and is still,65 by many, considered a prenatal phenome-
non. In 1978, hematopoietic stem cells were discovered in
human cord blood,h and it was in 1981 that the termEmbryonic
Stem Cell66 entered the medical lexicon, after pluripotent stem
cells were derived from the inner cell massi of a mouse em-
bryo.66,67 Finally, in 1998, human embryonic stem cells (hESCs)
were derived from blastocyst-stage human embryos.68
Governing principles. The discovery of stem cells was
paralleled by investigations on the nature of cell growth.
Judah Folkman, a distinguished medical scientist, was at the
forefront of these inquiries during the 1970s. Folkman re-
ported the dependence of histogenesis on mass transport
requirements of the growing tissue structure69; the essence
of a substrate to cell shape, which in turn governed growth
and proliferation70; and the ability of dissociated cells to
create structures if presented with cues from their native
hCord Blood is the blood that remains in the placenta and in the
attached umbilical cord after childbirth.
iPluripotent mass of cells inside the early embryo, which form the
source of embryonic stem cells.
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environment.71,72 These observations necessitated the use of
scaffolds, analogous to cellular matrices, and morphogens
(growth factors, hormones, etc.) to supplement growth of
cells and their development into tissues. Furthermore, Folk-
man’s conclusions on the importance of vascularization to the
growth of solid tumors, which could easily be extended tomost
developing tissues, must have acted as the precursor to con-
struction of more sophisticated bioreactors capable of sup-
porting cellular growth in the third dimension. Several other
investigators, including Joseph Vacanti, had reported similar
results.73–76
Extending these principles to practice, William T. Green,
an orthopedic surgeon, in the late 1970s, used chondrocytes
to grow cartilage. Green77 seeded these progenitor cells onto
spicules of bone (the scaffold), which he implanted into
nude mice. His attempts were not particularly successful,
but his efforts spawned a theoretical approach that led to a
new methodology of experimental techniques. In 1985, Paul
S. Russell wrote a review on selective cell transplantation78;
an alternative approach to organ transplantation whereby
only a selective part of an organ or tissue would be trans-
planted. The concept had merit but was rife with logistical
challenges.79 Isolated cells implanted into tissues as cell
suspension would neither integrate with the tissue nor ini-
tiate regeneration due to lack of a template guiding those
processes.79 Metabolic needs of the cells constituted an
additional problem.79 The following years witnessed clas-
sical tissue engineering experiments, in the laboratory as
well as on human subjects, such as the one where a collagen
matrix seeded with fibroblasts was employed to create
neodermis.80 The basic platform had been laid.
However, it was only in the mid-1980s, when Joseph
Vacanti approached Robert Langer to design scaffolds ap-
propriate for cell delivery as opposed to seeding them on a
matrix, that TERM made its first serious impression as an
emerging technology.3,40,79,80 Vacanti and Langer’s efforts
resulted in the publication of Tissue Engineering,3 the most
heavily cited article in the field to date. Realizing the ben-
efits, this new field had to offer, a lot of centers, aiming to
explore its potential, had sprung up around the world by
mid-1990s.80 TERM entered public consciousness with the
BBC broadcast that featured auriculosaurus, the mouse with
the human ear80 (Fig. 7). During the 1990s, Balkrishan G.
Matapurkar successfully employed adult stem cells found in
the peritoneum—the membrane that forms the lining of the
abdominal cavity—to aid organ regeneration.81–84 Mata-
purkar and his team harnessed the metaplastic capacity of
these autogenic, pluripotent mesodermal stem cells to aid
the regeneration of certain urogenital tissues, also meso-
dermal in origin.82 Finally, in 2007, stem cell researchers
were able to induce pluripotency in adult stem cells.85,86 As
they are not derived from embryos, the induced pluripotent
stem cells may finally put an end to the ethical debates that
have impeded the use of hESCs. While the discovery of
stem cells was one of the most significant achievements of
the 20th century, and although techniques have emerged to
get around the ethical, legal, and logistical issues that have
hindered the progress in stem cell research, we have merely
witnessed, as evident in Figure 8, the tip of this iceberg.
The State of the Art
The early years of the 21st century have witnessed TERM
take major strides as a therapeutic rehabilitator, not only
building on certain ancient techniques but also making tan-
gible the stuff of legends and fiction. Availability of autolo-
gous or allogenic epidermal (Epicel, Epidex, Myskin,
ReCell), dermal (AlloDerm, Integra, Matriderm), and
dermoepidermal (Apligraf, Orcel) substitutes represent the
current advance87 made on the earliest form of TERM tech-
nique practiced as early as 2500BC in the Indian subconti-
nent. Regeneration of dentine-pulp complex using cells
encapsulated within scaffolds; treatment of periodontal de-
fects through guided bone regeneration membrane, growth
factors and cytokines; and replacement of lost teeth by trans-
plantation of the bioengineered tooth germ constitute state of
the art of the rudimentary practice of employing blue nacre
shells as functional dental substitutes (by the Mayans circa
600AD). These advancements have been reviewed by Abou
Neel et al.88 Transplantation of bone marrow stem cells (en-
capsulated within a suitable scaffold),89 to repair articular
cartilage (patellar, patellofemoral, and femoral)90 and os-
teochondral defects90 as well as local bone defects91 in humans
forms another significant achievement of a TERM therapy89
practiced first by the Egyptians. The use of TERM to treat
skeletal defects has been reviewed elsewhere.89,91,92
While TERM is still decades away from replicating the
feat mentioned in the Mahabharata and Faust, of creating
human forms within a phial, the existing technology has
made possible development and availability of tissues and,
very recently, organs for clinical applications. A bioengi-
neered vessel implanted to replace the right intermediate
pulmonary artery in a child suffering from single right
ventricle and pulmonary atresia epitomizes the state of the
art.93 The methodology employed consisted of harvesting
cells from a peripheral vein and seeding them in a biode-
gradable polymer, which was maintained in a bioreactor for
10 days. Imaging the patient 9 years postimplantation re-
vealed a patent graft.94 The same technology has been
exploited to bioengineer bladders14 and urethras.95 Post-
implantation follow-ups showed improved functionality and
compliance.94
Using the same technology, with the exception that a
human scaffold was employed, a trachea was bioengineered
ex vivo and implanted in a woman with end-stage bronch-
omalacia.12 A deceased donor trachea, which was decel-
lularized following retrieval, served as the scaffold within
which autologous epithelial cells (derived from bronchos-
copy samples) and chondrocytes (differentiated from
FIG. 7. The auriculosaurus. The ‘‘human-ear-bearing’’
mouse developed by the Vacanti laboratory that went onto
epitomize Tissue Engineering. License to reproduce the image
was obtained from the ª (2002) BBC Photo Library. Color
images available online at www.liebertpub.com/teb
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mesenchymal cells obtained from patient’s bone marrow),
were seeded.12 Before implantation, the construct was
maintained for 4 days in a bioreactor designed to address
seeding requirements, provide biomechanical cues, and
achieve good laboratory practice.94 This technology of
employing decellularized organ scaffolds is advantageous as
the native three-dimensional (3D) tissue architecture, vas-
cular tree, and ECM-related cues, all with high develop-
mental significance, seem to be well preserved94,96 in the
organ scaffold. A variety of complex modular organs have
now been bioengineered, some of which, such as the lar-
ynx97,98 and vagina,99 have found clinical use. We highly
recommend reviews87,98 including those by Orlando et al.94
and Badylak et al.96 on this topic.
The bioengineered tissue constructs thus developed re-
capitulate the native architecture, physiology, dynamic
conditions, intercellular, and cell–matrix interactions more
accurately than two-dimensional culture monolayers, ca-
daveric tissues, as well as animal models.100–103 As such,
these ex vivo constructs can be employed as preclinical
models for high-throughput drug screening,100,102 pharma-
cokinetic and pharmacodynamics analyses of drugs,102 and
device testing.100 The advantages offered by these ‘‘syn-
thetic’’ tissues include decreased costs, increased reproduc-
ibility, precise control over culture conditions, incorporation
of human cells, and systematic evaluation of the product be-
ing tested.100 The platforms utilized include spheroids and
cell sheet stacking, matrix-embedded, lithography,103 mi-
crofluidic cell culture, hollow-fiber, and multicellular layer
models.102 Specific examples, which have been reviewed
extensively here,100,102,103 include blood vessels for device
(stents)104,105 and drug testing106; bioengineered blood–brain
barriers to test drug permeability107 and disease model-
ling108–110; musculoskeletal tissue to optimize drugs aimed at
improving muscular growth and function,111 as well as to
evaluate the impact of prosthetic devices on muscular tis-
sues.112 Corneal tissue to conduct tests for toxicology and eye
irritancy113; skin to test for cytotoxicity,114 phototoxici-
ty,115,116 and wound healing117; and reproductive tissues to
study sexually transmitted infections, product efficacy,118–120
and, as models of the blood–testis barrier, to predict toxicity
and permeability in vivo,121,122 form prime examples of
in vitro models (reviewed here in Refs.100,102,103).
The most significant advantage, though, remains their
availability as a superior and more accurate alternative to
animal testing. After all, ‘‘*92% of all drugs that enter
clinical trials following extensive animal testing fail to
achieve FDA approval because they are not safe or not ef-
fective in humans,’’101 and about half of the remaining 8%
are either withdrawn or relabeled due to adverse effects that
go undetected during animal testing.101 This endeavor
constitutes a quantum leap in making TERM a more humane
academic, research, and technological enterprise.
Within the TERM paradigm, the ‘‘product is the pro-
cess.’’123 The phrase implies that efficacy and functionality
of TERM products is intimately linked with product de-
sign and manufacturing. This is evident by the fact that
manufacturing processes responsible for the aforementioned
constructs has itself undergone transition from being man-
ual, inherently variable, static, and noncompliant to automated,
FIG. 8. Ear growth on the arm. Figure 7 presented the auriculosaurus, the mouse with a human ear. Similar principles
were employed by a team of surgeons to grow an external ear for this patient on her own arm. The set of images show the
compromised organ, perfusion to meet the transport demands of the synthetically growing new organ, the fully developed
organ, and, finally, its attachment to the patient. Cartilage for the new ear was derived from the patient’s ribs, matched with
her right ear, and implanted under the arm for growth. The work was carried on by surgeons led by Dr. Patric Byrne at the
Johns Hopkins University in 2012. The photographs issued along a media release belong to the public domain. The set
of images was retrieved from an online article published by CBS Baltimore.157 Color images available online at www
.liebertpub.com/teb
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dynamic, reproducible, and increasingly compliant with
current good manufacturing practices (GMP).123,124 The
state of the art in TERM manufacturing constitutes robotic
systems, such as the CompacT SelecT,125 to conduct auto-
mated cell culture124; computer-assisted bioprinting to
manufacture two- and three-dimensional biological patterns
to recapitulate the microenvironmental niche more precise-
ly2,126,127; and bioreactors that can perform multiple roles
such as nutrient and waste transport, mechanical condi-
tioning, cell seeding, supporting cell viability, and promot-
ing their 3D organization.128 These accomplishments by no
means represent the peak of this systematic evolution. Quite
the contrary, the automated procedures and manufacturing
processes are being continuously scrutinized and optimized,
using a variety of quality control tools, such as six-sigma
and, the data-driven, Define, Measure, Analyze, Improve
and Control (DMAIC) tool.123,124 Of significant value has
been the development of mathematical techniques60,129 in
synergy with the availability of increasingly powerful and
sophisticated semi-conductor chips and customized way of
packaging digital computing services.60 Mathematical for-
mulations, thus reinforced, have not only guided the design
and development of devices, such as the bioreactor, em-
ployed to synthesize TERM products, they have also made
available previously inaccessible data, such as flow profiles
and concentration gradients within a physical construct and
the cells’ response to them.128,130–136
New Frontiers and Future Directions
As is the nature of scientific revolutions, the information
sourced by the scientific community until the late 1980s
answered certain fundamental questions and thereby pro-
vided the impetus behind TERM acquiring a formal
framework to operate with. And, although the holy grail137
of TERM—that of developing vascularized, fully func-
tional, complex bioengineered tissues and organs—still lies
out of reach, the foregoing efforts have brought the com-
munity ever so closer to achieving that coveted eventuality.
However, a lot of work is still required to overcome grass
root challenges that stymie further advancement. These in-
clude the need for: increased cell expansion,137 more so-
phisticated in vitro systems that can expose cells to
physiologically relevant developmental cues,101 resistance
of implantable scaffolds against stricture,93 better drug
screening models, ensuring product bioneutrality rather than
inducing product tolerance in the patient, and developing
more sophisticated bioreactors capable of capturing the
niche characteristics of the targeted tissue/organ.101,128
Scientific investigators of the 20th century, armed with
verified principles and sophisticated apparatuses that can
recreate tissue microenvironments with great fidelity, made
major breakthroughs that shaped the course of future in-
vestigations. These included the ability to sustain organ and
cellular growth ex vivo,47,138,139 determining the impact of
the microenvironment on cellular behaviour,71,72 under-
standing the nature of interactions between cells (e.g.,
contact inhibition),46 and introducing the classical tissue
engineering technique of transplanting into the human body
cells seeded within polymeric scaffolds.77 In doing so, these
investigators exposed certain other questions, which re-
quired a new paradigm of exploration. One of these, still
relevant questions, pertains the induction of ex vivo histo-
genesis in a growing population of cells, for which decel-
lularized scaffolds have been recently utilized. The most
immediate of these include quantifying the complexity in-
herent in biological systems129 as well as gaining under-
standing of how much complexity is actually required to
create a functional tissue.101 This is a multipronged problem
that calls for integration of developmental biology meth-
odologies with those of TERM, but more importantly, the
application of computational approaches in developmental
biology to quantify the cellular niche. The latter, however, is
not an attempt to impose a way of investigation on another.
In fact, the computational TERM community must also rise
to the occasion and advance their techniques and approaches
to address the challenges of capturing biocomplexity. An
example of this collective endeavor is the principle of Dy-
namic Assimilation, proposed by Kaul in his doctoral the-
sis,140 which serves as the touchstone of performance for
computational platforms developed to analyze biocom-
plexity, especially in the TERM context. The underlying
idea being that once a system is quantified, the information
can then be applied to create scaffolds, conditioning tools,
and bioreactors that are based on the niche characteristics of
the targeted tissue/organ—a concept that has gained wide
attention.17,96,101,128,137
A significant challenge, however, remains non-
technological. As technologies often do, TERM, in the wake
of its advancements, has already established itself as a sig-
nificant player on the economic landscape. Despite, how-
ever, its vast clinical and commercial potential, regenerative
medicine has thus far underperformed,141 with the industry
in aggregate yet to make a profit. A multitude of nonquan-
tifiable reasons have contributed to this modest performance
of TERM industry. These include extraneous factors such as
misconceptions regarding the genuine achievements of the
sector,142 lack of strong political leadership,142 the histori-
cal lack of an industry voice,143,144 among others.145,146
Regulatory challenges,9,147 such as lack of quality control
biomarkers and potency markers, process and product var-
iability, risk factors associated with operator handling,
continue to impede the marketability of TERM-based
products. Similarly, a complex Intellectual Property situa-
tion, parallel to the biotech industry,148 owing to uncertain
outcomes with poorly defined and overlapping patents
constitutes another reason behind TERM’s modest industrial
and clinical translation. This is perhaps the most challenging
and unique hurdle that TERM faces, overcoming which
necessitates collaboration between scientists, innovators,
entrepreneurs, and policy makers. Progress, however, is
being continuously made, although at a glacial pace, in this
regard with the identification of business models (‘‘inte-
grated,’’ ‘‘fully integrated,’’ and ‘‘royalty model’’),87 ap-
preciation of the distinctions between TERM and nonliving
medical products,87,137 shift from the conventional pharma-
ceutical manufacturing ethos based on economies of scale,87
and introduction of quality control and GMP toward the
development of TERM products.9,123,149
Conclusion
TERM has completed its initial iteration. Initial because
little conceptual advance has been made since the early
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years of the 20th century when efforts to grow cellular
structure ex vivo were first realized. The push back then was
to create better media, more sophisticated 3D perfusion
systems, scaffolds capable of architectural and mechanical
conditioning, and making cell culture more of a science than
art. In realizing the technological advances, which now
constitute state of the art (decellularized scaffolds, a mul-
titude of bioreactors, and robotic culture systems), humanity
was acquainted with innovative therapies, which had until
recently belonged in the realm of fiction. These exciting
accomplishments left in their wake some more heretofore
unconsidered questions, not all scientific, exposing newer
horizons, which promise, in the most stunning manner, to
usher a new dawn of scientific, technological, industrial, and
regulatory endeavors, as discussed in the last section. Initial
also because the signature of the next iteration can be dis-
tinctly identified from the first and is embodied in the col-
lective effort to recapitulate the microenvironmental niche
through the use of bioprinters, condensing laboratory into a
computer and experiments into a code as part of the third
approach,150 employing the emergent151,152 paradigm for
understanding cellular behavior, and moving to an inte-
grated approach to better understand, develop, and test
TERM products. The TERM community stands at the edge
of another transition with its horizon irrevocably broadened.
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